Clinical Trials Directory

Trials / Completed

CompletedNCT01964547

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
121 (actual)
Sponsor
Jazz Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period of 48 weeks. Secondary objectives were to evaluate the effect of Sativex on mood and spasticity and to assess the safety and tolerability of Sativex.

Detailed description

Eligible patients entered this 50 week multicenter, double-blind, randomised, placebo-controlled, parallel group study which evaluated the effect of Sativex on cognitive performance. At each scheduled clinic visit, patients were assessed for cognitive performance, mood, severity of spasticity, use of investigational medicinal products and number of visits to a healthcare professional. Primary efficacy comparisons were made between scores recorded during baseline and scores recorded at the end of treatment.

Conditions

Interventions

TypeNameDescription
DRUGSativexPatients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
DRUGPlaceboPatients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).

Timeline

Start date
2012-01-01
Primary completion
2013-05-01
Completion
2013-05-01
First posted
2013-10-17
Last updated
2023-01-12
Results posted
2014-05-02

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT01964547. Inclusion in this directory is not an endorsement.